View Future GrowthUbionLtd 과거 순이익 실적과거 기준 점검 0/6UbionLtd 의 수입은 연평균 -15.5%의 비율로 감소해 온 반면, Consumer Services 산업은 연평균 4.2%의 비율로 증가했습니다. 매출은 연평균 15.2%의 비율로 감소해 왔습니다.핵심 정보-15.48%순이익 성장률-20.51%주당순이익(EPS) 성장률Consumer Services 산업 성장률13.57%매출 성장률-15.18%자기자본이익률-0.50%순이익률-0.043%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).모든 업데이트 보기Recent updates공시 • Apr 14Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on October 14, 2026. As of April 12, 2026, the company had 580,379 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.New Risk • Feb 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩20.6b market cap, or US$14.3m).공시 • Jan 21Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on July 22, 2026. As of January 20, 2026, the company had 0 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.분석 기사 • Aug 22These 4 Measures Indicate That UbionLtd (KOSDAQ:084440) Is Using Debt ExtensivelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.분석 기사 • Dec 18UbionLtd (KOSDAQ:084440) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).공시 • Dec 13Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024, at 11:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South KoreaNew Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 4.5% over the past year. Minor Risk Market cap is less than US$100m (₩15.1b market cap, or US$10.7m).Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩38.3b market cap, or US$29.6m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Is New 90 Day High Low • Feb 24New 90-day high: ₩5,050The company is up 32% from its price of ₩3,825 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 14New 90-day low: ₩3,150The company is down 6.0% from its price of ₩3,350 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 28New 90-day high: ₩3,700The company is up 24% from its price of ₩2,990 on 30 July 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day high: ₩3,600The company is up 21% from its price of ₩2,980 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is down 3.0% over the same period.매출 및 비용 세부 내역UbionLtd가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A084440 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 2530,716-1312,4141,99330 Sep 2533,6841,34012,4442,04130 Jun 2537,36728014,0221,31231 Mar 2537,31318213,1981,31231 Dec 2436,212-1,18813,0391,43830 Sep 2433,282-2,80010,9972,13530 Jun 2431,251-2,4839,8302,44731 Mar 2429,884-2,0639,1872,44731 Dec 2331,728-2927,9033,17130 Sep 2331,832-5449,1622,47930 Jun 2332,7243649,1642,29030 Sep 2231,4612,1519,3951,690양질의 수익: A084440 은(는) 현재 수익성이 없습니다.이익 마진 증가: A084440는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A084440은 수익성이 없으며 지난 5년 동안 손실이 연평균 15.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A084440의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A084440은 수익성이 없어 지난 해 수익 성장률을 Consumer Services 업계(37.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A084440는 현재 수익성이 없으므로 자본 수익률이 음수(-0.5%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YConsumer-services 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 07:37종가2026/05/21 00:00수익2025/12/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ubion Co.Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.
Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).
Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).
Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).
공시 • Apr 14Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on October 14, 2026. As of April 12, 2026, the company had 580,379 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.
Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.
New Risk • Feb 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩20.6b market cap, or US$14.3m).
공시 • Jan 21Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on July 22, 2026. As of January 20, 2026, the company had 0 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.
Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
분석 기사 • Aug 22These 4 Measures Indicate That UbionLtd (KOSDAQ:084440) Is Using Debt ExtensivelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
분석 기사 • Dec 18UbionLtd (KOSDAQ:084440) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).
공시 • Dec 13Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024, at 11:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Korea
New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 4.5% over the past year. Minor Risk Market cap is less than US$100m (₩15.1b market cap, or US$10.7m).
Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).
Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).
New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩38.3b market cap, or US$29.6m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Is New 90 Day High Low • Feb 24New 90-day high: ₩5,050The company is up 32% from its price of ₩3,825 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 14New 90-day low: ₩3,150The company is down 6.0% from its price of ₩3,350 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 28New 90-day high: ₩3,700The company is up 24% from its price of ₩2,990 on 30 July 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day high: ₩3,600The company is up 21% from its price of ₩2,980 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is down 3.0% over the same period.